A "Man Van" deployed in disadvantaged communities can help identify men at high risk for prostate cancer, according to a ...

A recent study published in the Journal of Cancer Research and Clinical Oncology explored genetic predictors of prostate cancer progression to help identify its clinical outcomes.

Nearly one in eight men will be diagnosed with prostate cancer and, as a new UCSF study finds, significantly more of these ...

The following is a summary of “Application of mean maximum Young’s modulus value as a new parameter for differential ...

The PORTOS assay could indicate when or when not to offer dose-escalated radiation for localized prostate cancer.

Serum testosterone (T) recovery to normal levels is associated with a significant improvement in overall survival in patients ...

Real-world data support trial data on the use of lutetium-177 PSMA-617 in patients with PSMA-positive, metastatic castration-resistant prostate cancer.

Radium-223 is an alpha-emitting radiopharmaceutical that accumulates in areas of high bone turnover and has demonstrated a survival benefit in metastatic prostate cancer, 1 but its benefits as a ...

GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Glenn Bauman discussing a prospective provincial registry of PSMA PET/CT for recurrent prostate cancer. While most ...

Providence Alaska Medical Center will be the first in the state to offer Pluvicto, an innovative therapy for metastatic ...

A systematic review and meta-analysis explored the relationship between androgen deprivation therapy and risk for heart failure in men with prostate cancer who were treated with ADT. A meta-analysis ...

Experts from Oxford University examined the impact of 164 environmental factors and genetic risks for 22 major diseases in ...